Novel Treatments for Chronic Liver Disease

ContraVir seeks to develop and commercialize novel drug treatments to improve the lives of patients suffering from chronic hepatitis B, C and D (HBV, HVC, HDV) and non-alcoholic steatohepatitis (NASH).

Pipeline Newsroom Investors

 

Combination Therapies for Hepatitis B

ContraVir is developing potentially curative combination therapies for chronic hepatitis B based on novel antiviral compounds.

TXL™ CRV431 Opportunity